진양제약
Financials
Valuation Metrics
진양제약's Market Cap is ₩549B. At end of 2025 it was ₩711B. Ranked #1657 of 2,436 in KR market (top 68%), #984 of 1,649 on KOSDAQ (top 60%), #183 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 78%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 54.91B KRW | KR#1,657/2,436 Sec#183/234 |
| Revenue | 122.15B KRW | KR#1,287/2,436 Sec#82/234 |
| Net Income | 22.29B KRW | KR#616/2,436 Sec#40/234 |
| Total Assets | 271.49B KRW | KR#1,066/2,436 Sec#75/234 |
| Net Assets | 159.98B KRW | KR#1,060/2,436 Sec#76/234 |
| Employees | 213 | KR#1,043/2,436 Sec#87/234 |
| Value | ||
| P/E | 2.46x | KR#79/2,436 Sec#4/234 |
| P/B | 0.34x | KR#447/2,436 Sec#15/234 |
| PEG | 36.18x | KR#843/2,436 Sec#58/234 |
| P/S | 0.45x | KR#861/2,436 Sec#30/234 |
| EV/EBITDA | 62.45x | KR#1,400/2,436 Sec#96/234 |
| FCF Yield | -0.33% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | 13.93% | KR#282/2,436 Sec#17/234 |
| ROA | 8.21% | KR#317/2,436 Sec#23/234 |
| Op. Margin | 1.68% | KR#1,399/2,436 Sec#102/234 |
| Revenue Growth | 4.72% | KR#1,174/2,436 Sec#109/234 |
| Earnings Growth | 0.07% | KR#898/2,436 Sec#61/234 |
| Financial Health | ||
| Debt Ratio | 169.71% | KR#1,439/2,436 Sec#165/234 |
| Total Debt | 75.84B KRW | KR#820/2,436 Sec#58/234 |
| FCF | -179.1M KRW | KR#1,233/2,436 Sec#93/234 |
| Cash | 2.71B KRW | KR#2,181/2,436 Sec#209/234 |
| Current Ratio | 0.52x | KR#2,244/2,436 Sec#214/234 |
| Net Debt/EBITDA | 35.67x | KR#1,500/2,436 Sec#108/234 |
| Dividend | ||
| Div. Yield | 3.91% | KR#457/2,436 Sec#15/234 |
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -35.03% | KR#1,687/2,436 Sec#142/234 |
| 1M Return | 2.78% | KR#478/2,436 Sec#34/234 |
| From 52W High | -39.86% | KR#751/2,436 Sec#51/234 |
| 1Y MDD | -48.96% | KR#887/2,436 Sec#71/234 |
| Trading | ||
| Volume | 35,074 shares | KR#1,850/2,436 Sec#179/234 |
| Foreign Own. | 2.94% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 1,652 KRW | KR#446/2,436 Sec#29/234 |
| BPS | 11,318 KRW | KR#864/2,436 Sec#63/234 |
Company Info
Jinyang Pharmaceutical, a mid-sized company, was established in 1971 for manufacturing and selling pharmaceuticals, converted to a corporation in 1978, and listed on KOSDAQ in 2000. It produces prescription and over-the-counter drugs, with a focus on the circulatory system segment, aiming for differentiation through new drug development from its generic-centric business structure. The company pursues substantial growth by strengthening marketing for its core circulatory products, investing in R&D, and developing new products. It is also preparing to launch new products through domestic and international patents and technology partnerships. Jinyang Pharmaceutical is headquartered in Seocho-gu, Seoul.